[Are therapeutic LDL goals justified? Controversies between the European and American guidelines]

Medwave. 2016 Dec 30;16(Suppl4):e6825. doi: 10.5867/medwave.2016.6825.
[Article in Spanish]

Abstract

Dyslipidemia is one of the most important risk factors of the cardiovascular disease, so its treatment is one of the key strategies of cardiovascular prevention. Statins have been consolidated as the reference treatment for the reduction of serum cholesterol levels. There are some divergences in the treatment of dyslipidemia between American and European guidelines. This narrative review discusses the key points of this controversy.

La dislipemia es uno de los factores de riesgo más importantes de las enfermedades cardiovasculares, por lo que su tratamiento es una de las estrategias claves de la prevención cardiovascular. Las estatinas se han consolidado como el tratamiento de referencia para la reducción de los niveles séricos de colesterol. Existen algunas divergencias entre las guías americana y europea en el tratamiento de la dislipemia. En esta revisión narrativa se discuten los puntos clave de esta controversia.

Keywords: LDL cholesterol; cardiovascular disease; statins; dyslipidemia.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol, LDL / blood*
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy*
  • Europe
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Practice Guidelines as Topic
  • Risk Factors
  • United States

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors